blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

Latvia joins the Federated Register
Click here for more information on the Federated Register.

2025-04-16

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2582721

EP2582721 - ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION [Right-click to bookmark this link]
Former [2013/17]ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUIZATION
[2018/27]
StatusNo opposition filed within time limit
Status updated on  28.06.2019
Database last updated on 26.04.2025
FormerThe patent has been granted
Status updated on  20.07.2018
FormerGrant of patent is intended
Status updated on  08.02.2018
FormerExamination is in progress
Status updated on  12.12.2016
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Trellis Bioscience, LLC
845 Oak Grove Ave, Suite 202
Menlo Park, CA 94025 / US
[2018/25]
Former [2015/18]For all designated states
Trellis Bioscience, LLC
1505-B O'Brien Dr.
Menlo Park, CA 94025 / US
Former [2013/17]For all designated states
Trellis Bioscience, LLC
2-B Corporate Drive
South San Francisco, CA 94080 / US
Inventor(s)01 / KAUVAR, Lawrence, M.
1438 Green Street, 7a
San Francisco, CA 94109 / US
02 / ELLSWORTH, Stote
578 Lowell Avenue
Palo Alto, CA 94301 / US
03 / USINGER, William
1056 Roderick Court
Lafayette, CA 94549 / US
04 / MCCUTCHEON, Krista, Maureen
1512 Carol Avenue
Burlingame, CA 94010 / US
05 / PARK, Minha
275 Mendocino Street
Brisbane, CA 94005 / US
 [2013/43]
Former [2013/17]01 / KAUVAR, Lawrence, M.
1438 Green Street
7a
San Francisco CA 94109 / US
02 / ELLSWORTH, Stote
578 Lowell Avenue
Ralo Alto CA 94301 / US
03 / USINGER, William
1056 Roderick Court
Lafayette CA 94549 / US
04 / MCCUTCHEON, Krista, Maureen
1512 Carol Avenue
Burlingame CA 94010 / US
05 / PARK, Minha
275 Mendocino Street
Brisbane CA 94005 / US
Representative(s)V.O.
P.O. Box 87930
2508 DH Den Haag / NL
[2018/34]
Former [2013/17]Jansen, Cornelis Marinus, et al
VEREENIGDE Johan de Wittlaan 7
2517 JR Den Haag / NL
Application number, filing date11796555.817.06.2011
[2018/34]
WO2011US40982
Priority number, dateUS20100355978P17.06.2010         Original published format: US 355978 P
US201161443103P15.02.2011         Original published format: US 201161443103 P
US201161445455P22.02.2011         Original published format: US 201161445455 P
[2013/17]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011160083
Date:22.12.2011
Language:EN
[2011/51]
Type: A1 Application with search report 
No.:EP2582721
Date:24.04.2013
Language:EN
The application published by WIPO in one of the EPO official languages on 22.12.2011 takes the place of the publication of the European patent application.
[2013/17]
Type: B1 Patent specification 
No.:EP2582721
Date:22.08.2018
Language:EN
[2018/34]
Search report(s)International search report - published on:US22.12.2011
(Supplementary) European search report - dispatched on:EP22.10.2013
ClassificationIPC:A61K39/395, C07K16/10, A61P31/16
[2013/47]
CPC:
C07K16/1018 (EP,CN,RU,US); C07K16/10 (KR); A61K38/17 (KR);
A61K38/18 (KR); A61K39/395 (KR); A61K47/42 (KR);
A61K48/00 (KR); A61P31/00 (EP); A61P31/16 (EP);
C07K14/435 (KR); C07K14/475 (KR); C07K16/18 (KR);
C07K16/22 (KR); C07K16/28 (KR); A61K2039/505 (EP,RU,US);
C07K2317/21 (EP,RU,US); C07K2317/33 (EP,RU,US); C07K2317/34 (EP,RU,US);
C07K2317/56 (CN); C07K2317/565 (CN); C07K2317/76 (EP,RU,US);
C07K2317/92 (EP,RU,US) (-)
Former IPC [2013/17]C07K16/00, A61K39/395
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2013/17]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:ANTIKÖRPER ZUR PASSIVEN INFLUENZA-IMMUNISIERUNG[2013/17]
English:ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION[2018/27]
French:ANTICORPS UTILES DANS L'IMMUNISATION PASSIVE CONTRE LA GRIPPE[2013/17]
Former [2013/17]ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUIZATION
Entry into regional phase17.01.2013National basic fee paid 
17.01.2013Search fee paid 
17.01.2013Designation fee(s) paid 
17.01.2013Examination fee paid 
Examination procedure17.01.2013Examination requested  [2013/17]
19.05.2014Amendment by applicant (claims and/or description)
01.09.2015Despatch of a communication from the examining division (Time limit: M06)
07.03.2016Reply to a communication from the examining division
06.05.2016Despatch of a communication from the examining division (Time limit: M06)
13.12.2016Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
13.02.2017Reply to a communication from the examining division
05.01.2018Cancellation of oral proceeding that was planned for 11.01.2018
11.01.2018Date of oral proceedings (cancelled)
09.02.2018Communication of intention to grant the patent
24.05.2018Fee for grant paid
24.05.2018Fee for publishing/printing paid
24.05.2018Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  01.09.2015
Opposition(s)23.05.2019No opposition filed within time limit [2019/31]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
13.02.2017Request for further processing filed
13.02.2017Full payment received (date of receipt of payment)
Request granted
21.02.2017Decision despatched
Fees paidRenewal fee
10.06.2013Renewal fee patent year 03
31.03.2014Renewal fee patent year 04
10.06.2015Renewal fee patent year 05
27.06.2016Renewal fee patent year 06
16.06.2017Renewal fee patent year 07
11.06.2018Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.06.2011
AL22.08.2018
CY22.08.2018
CZ22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
MK22.08.2018
MT22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
TR22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
PT22.12.2018
[2022/31]
Former [2021/34]HU17.06.2011
AL22.08.2018
CY22.08.2018
CZ22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
MT22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
TR22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
PT22.12.2018
Former [2021/32]HU17.06.2011
AL22.08.2018
CY22.08.2018
CZ22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
TR22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
PT22.12.2018
Former [2021/26]AL22.08.2018
CY22.08.2018
CZ22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
TR22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
PT22.12.2018
Former [2020/29]AL22.08.2018
CZ22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
TR22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
PT22.12.2018
Former [2020/17]AL22.08.2018
CZ22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
TR22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2020/08]AL22.08.2018
CZ22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
MC22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/37]AL22.08.2018
CZ22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SI22.08.2018
SK22.08.2018
SM22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/26]AL22.08.2018
CZ22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SK22.08.2018
SM22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/24]AL22.08.2018
CZ22.08.2018
EE22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
SK22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/22]AL22.08.2018
CZ22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
PL22.08.2018
RO22.08.2018
RS22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/12]AL22.08.2018
FI22.08.2018
HR22.08.2018
LT22.08.2018
LV22.08.2018
RS22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/11]FI22.08.2018
HR22.08.2018
LT22.08.2018
RS22.08.2018
BG22.11.2018
NO22.11.2018
GR23.11.2018
IS22.12.2018
Former [2019/08]FI22.08.2018
LT22.08.2018
NO22.11.2018
IS22.12.2018
Former [2019/07]LT22.08.2018
Documents cited:Search[X]WO2008028946  (CRUCELL HOLLAND BV [NL], et al) [X] 1,3-7,12,13 * example 12 *;
 [XI]WO2010010466  (INST RESEARCH IN BIOMEDICINE [CH], et al) [X] 1-3,5-7,12,13 * table 4 * * examples 1-2 * * page 29 * [I] 8-11,14-16;
 [XI]WO2010010467  (INST RESEARCH IN BIOMEDICINE [CH], et al) [X] 1,3,5,6,12,13 * sequences 60, 61 * * tables 1,4,6 * * page 40, lines 1-2 * * example 4 * [I] 14-16;
 [XP]WO2010074656  (TEMASEK LIFE SCIENCES LAB LTD [SG], et al) [XP] 1-7,12,13 * page 11, lines 1-4 * * example 5 * * claim 6 *;
 [E]WO2011117848  (POMONA RICERCA SRL [IT], et al) [E] 1,3,5,12,13 * tables 1,4 * * pages 5,17,18 * * page 20 *;
 [E]WO2012045001  (UNIV VANDERBILT [US], et al) [E] 1,3,5 * tables A, 1.1 *;
 [XP]  - DAVIDE CORTI ET AL, "A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US; THE INSTITUTION OF ELECTRICAL ENGINEERS, STEVENAGE, GB, vol. 333, no. 6044, doi:10.1126/SCIENCE.1205669, ISSN 0036-8075, (20110812), pages 850 - 856, (20110728), XP002689150 [XP] 1-3,5-7,12,13 * page 854, column left * * figure 6D *

DOI:   http://dx.doi.org/10.1126/science.1205669
 [X]  - PRABHU NAYANA ET AL, "Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection.", JOURNAL OF VIROLOGY MAR 2009, (200903), vol. 83, no. 6, ISSN 1098-5514, pages 2553 - 2562, XP002714198 [X] 1-7,12,13 * paragraph [abstract] * * page 2554, column right * * page 2556, column left *

DOI:   http://dx.doi.org/10.1128/JVI.02165-08
 [X]  - ZIEGLER T ET AL, "Type- and subtype-specific detection of influenza viruses in clinical specimens by rapid culture assay", JOURNAL OF CLINICAL MICROBIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, (19950201), vol. 33, no. 2, ISSN 0095-1137, pages 318 - 321, XP002541924 [X] 1,3 * page 319, column left * * table 2 *
 [X]  - KOSTOLANSKÝ F ET AL, "Antibody response to hidden epitope of influenza A haemagglutinin elicited by anti-idiotypic antibodies.", ACTA VIROLOGICA AUG 1994, (199408), vol. 38, no. 4, ISSN 0001-723X, pages 215 - 222, XP008165167 [X] 1,3 * page 215 *
 [X]  - EKIERT DAMIAN C ET AL, "Antibody Recognition of a Highly Conserved Influenza Virus Epitope", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, (20090401), vol. 324, no. 5924, ISSN 0036-8075, pages 246 - 251, XP009144786 [X] 1,3-7,12,13 * page 250, column middle * * page 249, column middle * * page 248, column middle *
 [A]  - DONIS R O ET AL, "Distinct lineages of influenza virus H4 hemagglutinin genes in different regions of the world", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 169, no. 2, ISSN 0042-6822, (19890401), pages 408 - 417, (19890401), XP026430699 [A] 1-16 * figure 3 *
International search[A]WO2007134327  (SEA LANE BIOTECHNOLOGIES LLC [US], et al);
 [Y]WO2009079259  (DANA FARBER CANCER INST INC [US], et al);
 [Y]WO2009121004  (SEA LANE BIOTECHNOLOGIES LLC [US], et al);
 [A]US2009311265  (VAN DEN BRINK EDWARD NORBERT [NL], et al);
 [A]WO2010022120  (REGENERON PHARMA [US], et al);
 [A]US2010086555  (LANZAVECCHIA ANTONIO [CH]);
 [A]US7696330  (MEULEN JAN H TER [NL], et al);
 [X]  - STEEL ET AL., "Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain", MBIO, (201004), vol. 1, no. 1, pages 1 - 9, XP002676044

DOI:   http://dx.doi.org/10.1128/mbio.00018-10
 [A]  - KUBOTA-KOKETSU ET AL., "Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (2009), vol. 387, pages 180 - 185, XP026378974

DOI:   http://dx.doi.org/10.1016/j.bbrc.2009.06.151
 [A]  - BRIGHT ET AL., "Cross-Clade Protective Immune Responses to Influenza Viruses with H5N1 HA and NA Elicited by an Influenza Virus-Like Particle.", PLOS ONE, (200801), vol. 3, no. E1501, pages 1 - 14, XP009116084

DOI:   http://dx.doi.org/10.1371/journal.pone.0001501
ExaminationWO2008076379
    - "Competitive inhibition", INTERNET CITATION, (20110913), pages 1 - 5, URL: http://en.wikipedia.org/wiki/Competitive_inhibition, (20111003), XP002660444
    - THROSBY MARK ET AL, "Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.", PLOS ONE 2008, (2008), vol. 3, no. 12, ISSN 1932-6203, page e3942
    - GERSHONI JONATHAN M ET AL, "Epitope mapping - The first step in developing epitope-based vaccines", BIODRUGS, ADIS INTERNATIONAL LTD, NZ, (20070101), vol. 21, no. 3, doi:10.2165/00063030-200721030-00002, ISSN 1173-8804, pages 145 - 156, XP009103541

DOI:   http://dx.doi.org/10.2165/00063030-200721030-00002
by applicantWO2004080403
 US7413868
    - BIANCHI, E. et al., J. Virol., (20050000), vol. 79, pages 7380 - 7388
    - ORCUTT KD; ACKERMAN ME; CIESLEWICZ M; QUIROZ E; SLUSARCZYK AL; FRANGIONI JV; WITTRUP KD, "A modular IgG-scFv bispecific antibody topology", Protein Eng Des Sel., (20100000), vol. 23, doi:doi:10.1093/protein/gzp077, pages 221 - 228, XP007914840

DOI:   http://dx.doi.org/10.1093/protein/gzp077
    - FITZGERALD J; LUGOVSKOY A, "Rational engineering of antibody therapeutics targeting multiple oncogene pathways", MAbs, (20110000), vol. 1, no. 3, page 3
    - BAEUERLE PA; REINHARDT C, "Bispecific T-cell engaging antibodies for cancer therapy", Cancer Res., (20090000), vol. 69, doi:doi:10.1158/0008-5472.CAN-09-0547, pages 4941 - 4944, XP002665118

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-09-0547
    - THROSBY M. et al., PLoS One., (20080000), vol. 3, page e3942
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.